GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences …

LONDON, April 18, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, noted that the American Academy of Neurology (AAN) issued a press release today announcing positive results from a second Phase 3 study (GWPCARE3) of Epidiolex® (cannabidiol or CBD) in children and adults with Lennox-Gastaut syndrome (LGS). The data will be presented at the upcoming meeting of the American Academy of Neurology (AAN) in Boston, MA.

In the GWPCARE3 study, adding Epidiolex to patients’ current treatment significantly reduced the frequency of drop seizures at both the 10 mg/kg/day and 20mg/kg/day doses. During the 14-week treatment period, patients taking both doses of Epidiolex saw a significantly greater median reduction in monthly drop seizures (37 percent and 42 percent, respectively) compared with a 17 percent reduction for

... read more at: https://globenewswire.com/news-release/2017/04/18/961885/0/en/GW-Pharmaceuticals-and-its-U-S-Subsidiary-Greenwich-Biosciences-Highlight-New-Epidiolex-cannabidiol-Data-Released-by-the-American-Academy-of-Neurology.html

Leave a Reply